EP Patent

EP3998069C0 — NANOPARTICLES CONTAINING SIROLIMUS AND AN ALBUMIN FOR USE IN THE TREATMENT OF EPITHELOID CELL TUMORS

Assigned to Abraxis Bioscience LLC · Expires 2024-12-11 · 1y expired

What this patent protects

Patent listed against Rapamune.

Drugs covered by this patent

Rapamune (sirolimus) · Pfizer

Patent Metadata

Patent number: EP3998069C0
Jurisdiction: EP
Classification: —
Expires: 2024-12-11
Drug substance claim: No
Drug product claim: No
Assignee: Abraxis Bioscience LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.